Skip to content
Open access

Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species

Aug 2026 · Antimicrobial Agents and Chemotherapy · Vol 70 · 0 citations · 54 references
Medicine

TL;DR

5-fluorouridine is identified as a promising antifungal candidate and C-5-halogenated nucleosides are established as a privileged scaffold for antifungal drug development.

Abstract

ABSTRACT The emergence of multidrug-resistant Candidozyma auris has created an urgent need for antifungals with novel mechanisms of action. We screened 121 nucleoside and nucleobase derivatives against C. auris and other clinically relevant Candida species to identify effective antimetabolite scaffolds. Among all compounds tested, only the C-5-fluorinated nucleosides 5-fluorouridine (5-FU) and 5-fluorocytidine exhibited potent antifungal activity. 5-FU demonstrated consistently low minimum inhibitory concentrations (0.5–10 µg/mL) across multiple Candida species, including fluconazole-resistant strains, and displayed fungicidal activity against C. auris at concentrations lower than several frontline antifungals. Uridine rescue assays confirmed competitive interference with endogenous uridine metabolism. Checkerboard assays revealed synergistic or additive interactions between 5-FU and clinically used azoles and echinocandins. Toxicity evaluation using plant, nematode, and human cell models showed minimal cytotoxicity even at concentrations far exceeding antifungal minimum inhibitory concentrations. In silico docking analyses revealed dual inhibition of thymidylate synthase and RNA polymerase III, explaining the fungicidal phenotype and broad-spectrum efficacy. These findings identify 5-fluorouridine as a promising antifungal candidate and establish C-5-halogenated nucleosides as a privileged scaffold for antifungal drug development.

Read PDF

Similar papers

Aug 2026

Rationally designed indole-Thiosemicarbazides as potent Ergosterol-targeting antifungal agents against Candida spp.

The combined antifungal, antibiofilm, mechanistic, structural, and computational findings identify compound 3d as the most promising, highlighting indole-thiosemicarbazides as a valuable scaffold for ergosterol-targeted antifungals effective against drug-sensitive and resistant Candida.

Vidyasagar, Shabnam Kumari, Ritu Raj Patel et al. · 0 citations
Open access Sep 2026

Discovery of a Caffeic Acid Thioamide with Potent Activity against Pathogenic Fungi and Fluconazole Tolerance-Eliminating Effects in Candida albicans

Compound F4 emerges as a promising lead for antifungal drug development, distinguished by its broad‑spectrum activity, antibiofilm properties, and unique capacity to eliminate FLC tolerance.

Jia-Yin Wang, Qin-Li Guo, Nan Chen et al. · 0 citations
Open access Sep 2026

Synergistic antifungal activity and mechanisms of dehydronuciferine combined with fluconazole against drug-resistant Candida albicans

D dehydronuciferine is identified as a promising antifungal chemosensitizer that enhances fluconazole efficacy against drug-resistant C. albicans through multitarget perturbation of resistance- and virulence-associated processes.

Xiu-Yun Li, Ai Zhang, Tajiguli Kupi et al. · 0 citations
Open access Aug 2026

Linker Engineering of Hybrid Triazole-Thiazolidine Antifungals Identifies a Promising Lead Against Drug-Resistant Candida Species

Systematic variation of linker architecture identified compound 28 as a promising exploratory antifungal lead, exhibiting sub-microgram MIC values against several Candida isolates, and retaining measurable activity against an azole-resistant C. albicans strain.

A. Y. Rudenko, Olga A Komarova, A. Y. Simonov et al. · 0 citations
Open access Sep 2026

Structure−Activity Relationship Profiling of Substituted N -Phthalimidopiperidine Analogs as Broad-Spectrum Antifungal Agents

SSD2032594 showed a survival benefit in the Caenorhabditis elegans nematode model of C. auris infection, resulting in a ∼30% higher survival rate, and is highlighted as a candidate for antifungal drug development, targeting infections caused by different fungal pathogens.

Matthew P. Dupuis, Nour M. Alkashef, Roman A. Matamoros et al. · 0 citations
Open access Aug 2026

Design and mechanistic evaluation of chalcone–quinoline–triazole hybrids as antifungal CYP51 inhibitors

Mechanistic investigations demonstrated that compound 7b markedly disrupted fungal sterol biosynthesis, as evidenced by significant ergosterol depletion, lanosterol accumulation, and a pronounced reduction in the ergosterol/lanosterol ratio across all tested Candida species.

R. Hendra, Rahmad Setiawan Rabby, Tengku Anggia Fitri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.